Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Osteoporosis International

Volumn 24, Issue 1, 2013, Pages 301-310

  McClung, M R ^a   Balske, A ^b   Burgio, D E ^c   Wenderoth, D ^d   Recker, R R ^e  

^a OREGON OSTEOPOROSIS CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

^c PROCTER AND GAMBLE COMPANY   (United States)

^d Warner Chilcott Deutschland GmbH   (Germany)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone mineral density; Delayed release; Enteric coated; Histomorphometry; Osteoporosis; Risedronate; Weekly

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE BIOPSY; BONE DENSITY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SPINE FRACTURE; TREATMENT DURATION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 84872362002     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2175-7     Document Type: Article

References (31)

1. McClung MR, Miller PD, Brown J, Zanchetta J, Bolognese MA, Benhamou C-L, Balske A, Burgio D, Sarley J, Recker RR (2012) Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet in the treatment of postmenopausal osteoporosis. Osteoporos Int 23(1):267-276
2. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2):75-85
3. Fleisch HA (1997) Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 29(1):55-62
4. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm 4(5):488-492
5. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453-1460
6. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013-1022
7. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44(1):153-159
8. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31(1):103-115
9. Genant HK, Wu CY, Van Kuik C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137-1148
10. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S (1988) Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3(2):133-144
11. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344-1352
12. Reginster JY, Minne HW, Sorensen O et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83-91
13. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333-340
14. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67(4):277-285
15. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74(2):129-135
16. Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20(4):433-439
17. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75(6):462-468
18. Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP (2004) Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 20(5):757-764
19. McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou C-L, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P (2012) Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int. doi: 10.1007/s00198-012-2056-0
20. Akagi Y, Sakaue T, Yoneyama E, Aoyama T (2011) Influence of mineral water on absorption of oral alendronate in rats. Yakugaku Zasshi 131(5):801-807, Japanese
21. Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD (2009) Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 20(11):1895-1902
22. Warner Chilcott. Atelvia® Prescribing Information. http://www.wcrx.com/pdfs/pi/pi-atelvia.pdf. Accessed 15 Jun 2012
23. Blümel JE, Castelo-Branco C, de la Cuadra G, Maciver L, Moreno M, Haya J (2003) Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects. J Obstet Gynaecol 23(3):278-281
24. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73(5):423-432
25. Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31(5):620-625
26. Ste-Marie EF, Sod E, Johnson T, Chines A (2004) Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75(6):469-476
27. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39(2):345-352
28. Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 21(10):1581-1590
29. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100(6):1475-1480
30. Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW, Denosumab Phase 3 Bone Histology Study Group (2010) Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25(10):2256-2265
31. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind trial. J Bone Miner Res 20(1):141-151